Finally, our data show that the cytokine‐induced upregulation of PD‐L1 on MPN cells can be disrupted by addition of JAK2‐targeting agents and BET/BRD4‐targeting drugs. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.